McKenna Mark C.'s most recent trade in Apogee Therapeutics Inc. was a trade of 14,461 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 17, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Apogee Therapeutics Inc. | Mark C. McKenna | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 14,461 | 14,461 | - | - | Stock Option (Right to Buy) | |
| Spyre Therapeutics Inc. | Mark C. McKenna | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| NewAmsterdam Pharma Compan... | Mark C. McKenna | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 32,500 | 32,500 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Compan... | Mark C. McKenna | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 6,960 | 6,960 | - | - | Ordinary Shares | |
| Apogee Therapeutics Inc. | Mark McKenna C. | Director | Purchase of securities on an exchange or from another person at price $ 49.85 per share. | 12 Dec 2024 | 12,500 | 20,000 | - | 49.9 | 623,125 | Common Stock |
| Apogee Therapeutics Inc. | C. Mark McKenna | Director | Purchase of securities on an exchange or from another person at price $ 49.02 per share. | 12 Dec 2024 | 7,500 | 7,500 | - | 49.0 | 367,650 | Common Stock |
| NewAmsterdam Pharma Compan... | Mark C. McKenna | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2024 | 72,500 | 72,500 | - | - | Option (right to buy) | |
| Apogee Therapeutics Inc. | Mark C. McKenna | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 10,370 | 10,370 | - | - | Stock Option (Right to Buy) | |
| Spyre Therapeutics Inc. | Mark McKenna C. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Apogee Therapeutics Inc. | McKenna Mark C. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2023 | 100,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Apogee Therapeutics Inc. | C. Mark McKenna | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2023 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) |